VITAERIS INC
Summary
Vitaeris is a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection.
Deals Overview
No teams exist
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.